Skin Cancer Diagnostics Company Files for $57 Million IPO

Skin Cancer Diagnostics Company Files for $57 Million IPO

Source: 
CP Wire
snippet: 

Castle Biosciences Filed the paperwork on 6/26/19 for their $57 Million IPO. The commercial stage company provides diagnostic and prognostic test for dermatologic cancers. Castle intends to tradeon NASDAQ under the symbol, “CSTL.”